By Chris Wack
Genmab AS and BioNTech SE said they are expanding their global strategic collaboration to develop and commercialize novel immunotherapies for the treatment of cancer patients.
Under the expansion, Genmab and BioNTech will jointly work to research, develop and commercialize novel monospecific antibody candidates for various cancer indications.
The companies have been working on the joint development of bispecific cancer antibodies aimed at improving immunotherapy options for cancer patients since 2015.
Under the expanded collaboration, the companies will jointly develop and commercialize, subject to regulatory approval, monospecific antibodies using Genmab's proprietary HexaBody technology platform. The first monospecific antibody candidate, GEN1053/BNT313, is expected to enter clinical trials by the end of 2022.
Under the terms of the agreement, the companies will equally share the development costs and potential future profit deriving from GEN1053/BNT313.
Write to Chris Wack at firstname.lastname@example.org
(END) Dow Jones Newswires
August 05, 2022 07:15 ET (11:15 GMT)Copyright (c) 2022 Dow Jones & Company, Inc.